InflaRx (IFRX) Receivables - Net (2017 - 2024)

InflaRx's (IFRX) quarterly Receivables - Net came in at $96172.2 in Q3 2024, up 276.39% quarter-over-quarter from $25551.3 in Q2 2024.

InflaRx (IFRX) Receivables - Net (2017 - 2024) Analysis & Trends

InflaRx has disclosed Receivables - Net across 4 years of filings, most recently posting $96172.2 for Q3 2024.

Receivables - Net for Q3 2024 came in at $96172.2, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $96172.2 (changed N/A YoY), and the FY2018 annual result was $12323.7, up 361.66% from the prior year.
Receivables - Net came in at $96172.2 for Q3 2024 at InflaRx, up from $25551.3 in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $96172.2 in Q3 2024 to a low of -$38285.6 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	723,416.35 Bn	723,416.32 Bn	-
2	Belite Bio	57,340.00 Bn	57,340.00 Bn	-
3	Quantum Biopharma	19,125.08 Bn	19,125.08 Bn	-
4	Legend Biotech	3,262.00 Bn	3,261.71 Bn	242.10 Mn
5	Akari Therapeutics	1,789.67 Bn	1,789.67 Bn	-
6	Evaxion A	1,480.39 Bn	1,480.37 Bn	-
7	Psyence Biomedical	241.78 Bn	241.78 Bn	-
8	Vertex Pharmaceuticals	113.54 Bn	106.29 Bn	2.59 Bn
9	Abivax	94.26 Bn	94.26 Bn	-
10	InflaRx	764.68 Mn	764.68 Mn	10,877.40

Download Data